You are here:

olaratumab (Lartruvo)

Advice

following a full submission considered under the end of life and ultra-orphan process:

olaratumab (Lartruvo®) is accepted  for restricted use within NHS Scotland.

Indication under review: In combination with doxorubicin for the treatment of adult patients with advanced soft-tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.

SMC restriction: for use in combination with doxorubicin as first-line treatment for advanced soft-tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.

In an open-label phase II study, olaratumab in combination with doxorubicin improved progression-free and overall survival compared with doxorubicin alone in patients with advanced soft-tissue sarcoma not amenable to surgery or radiotherapy.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of olaratumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: olaratumab (Lartruvo)
SMC Drug ID: 1273/17
Manufacturer: Eli Lilly and Company Ltd
Indication: In combination with doxorubicin for the treatment of adult patients with advanced soft-tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.
BNF Category:
Submission Type: Full submission
Status: Restricted
Date Advice Published: 13 November 2017

Back